Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study

Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis... Oncol Ther (2016) 4:275–286 DOI 10.1007/s40487-016-0032-0 ORIGINAL RESEARCH Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study . . . . Serafino Conforti Stefano Minardi Ludovica Conforti Salvatore Turano . . Stefania Bilotta Emmanuelle Vilardo Salvatore Palazzo Received: August 25, 2016 / Published online: October 7, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com minimize the impact of everolimus-associated ABSTRACT oral mucositis in patients with advanced cancer. Introduction: Stomatitis is a common and Methods: Patients receiving everolimus plus potentially dose-limiting adverse event of the exemestane for advanced breast cancer or mammalian target of rapamycin (mTOR) everolimus alone for advanced renal cancer were inhibitor therapy. To minimize dose eligible for inclusion. All patients were advised on reductions or treatment delays that may affect procedures to maintain good oral hygiene and therapeutic outcomes, management includes directed to use a dexamethasone-containing patient education, pain management galenical preparation at the first signs of strategies, and drug treatment. The aim of this mucositis. Questionnaires were administered at study was to evaluate the effectiveness of a baseline, and after cycles one, two, and three to topically-applied galenical preparation to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/topical-application-of-a-galenical-formulation-for-the-management-of-nfA5hbik8h
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0032-0
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:275–286 DOI 10.1007/s40487-016-0032-0 ORIGINAL RESEARCH Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study . . . . Serafino Conforti Stefano Minardi Ludovica Conforti Salvatore Turano . . Stefania Bilotta Emmanuelle Vilardo Salvatore Palazzo Received: August 25, 2016 / Published online: October 7, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com minimize the impact of everolimus-associated ABSTRACT oral mucositis in patients with advanced cancer. Introduction: Stomatitis is a common and Methods: Patients receiving everolimus plus potentially dose-limiting adverse event of the exemestane for advanced breast cancer or mammalian target of rapamycin (mTOR) everolimus alone for advanced renal cancer were inhibitor therapy. To minimize dose eligible for inclusion. All patients were advised on reductions or treatment delays that may affect procedures to maintain good oral hygiene and therapeutic outcomes, management includes directed to use a dexamethasone-containing patient education, pain management galenical preparation at the first signs of strategies, and drug treatment. The aim of this mucositis. Questionnaires were administered at study was to evaluate the effectiveness of a baseline, and after cycles one, two, and three to topically-applied galenical preparation to

Journal

Oncology and Therapy – Springer Journals

Published: Oct 7, 2016

References

  • Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
    Baselga, J; Campone, M; Piccart, M; Burris, HA; Rugo, HS; Sahmoud, T
  • Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
    Motzer, RJ; Escudier, B; Oudard, S; Hutson, TE; Porta, C; Bracarda, S
  • Everolimus for advanced pancreatic neuroendocrine tumors
    Yao, JC; Shah, MH; Ito, T; Bohas, CL; Wolin, EM; Cutsem, E
  • Common toxicities of mammalian target of rapamycin inhibitors
    Soefje, SA; Karnad, A; Brenner, AJ
  • An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
    Grünwald, V; Karakiewicz, PI; Bavbek, SE; Miller, K; Machiels, JP; Lee, SH
  • Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review
    Boers-Doets, CB; Epstein, JB; Raber-Durlacher, JE; Ouwerkerk, J; Logan, RM; Brakenhoff, JA
  • Mammalian target of rapamycin inhibitor-associated stomatitis
    Boers-Doets, CB; Raber-Durlacher, JE; Treister, NS; Epstein, JB; Arends, AB; Wiersma, DR
  • Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients
    Sonis, S; Treister, N; Chawla, S; Demetri, G; Haluska, F
  • Strategies for the management of adverse events associated with mTOR inhibitors
    Kaplan, B; Qazi, Y; Wellen, JR
  • Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
    Aapro, M; Andre, F; Blackwell, K; Calvo, E; Jahanzeb, M; Papazisis, K
  • Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
    Rugo, HS; Pritchard, KI; Gnant, M; Noguchi, S; Piccart, M; Hortobagyi, G
  • Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
    Peterson, ME
  • The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis
    Boers-Doets, CB; Lalla, RV
  • Breast cancer treatment with everolimus and exemestane for ER+ women: results of the 2nd interim analysis of the non-interventional trial BRAWO [Poster]
    Fasching, PA; Decker, T; Schneeweiss, A; Uleer, C; Förster, F; Wimberger, P
  • Everolimus in combination with exemestane in hormone receptor-positive locally advanced or metastatic breast cancer (BC) patients progressing on prior non-steroidal AI (NSAIs): Ballet study (CRAD001YIC04) [Poster]
    Jerusalem, G; Mariani, G; Ciruelos, EM; Martin, M; Tjan-Heijnen, VCG; Neven, P
  • Practical management of everolimus-related toxicities in patients with advanced solid tumors
    Grünwald, V; Weikert, S; Pavel, ME; Horsch, D; Luftner, D; Janni, W